Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection.
暂无分享,去创建一个
Jeffrey J. Fong | C. Mathias | Lucia Rose | Tiffany E Bias | Clinton B Mathias | Stacey B Trooskin | Jeffrey J Fong | S. Trooskin | T. Bias | Lucia Rosé
[1] M. Manns,et al. Peginterferon alfa-2b plus ribavirin for chronic hepatitis , 2002, The Lancet.
[2] M. Alter,et al. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.
[3] Diem-Kieu H. Ngo. FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) , 2008 .
[4] T. Marbury,et al. 1101 THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977 , 2012 .
[5] John McNally,et al. Sofosbuvir for previously untreated chronic hepatitis C infection. , 2013, The New England journal of medicine.
[6] E. Lawitz,et al. Pharmacokinetics, Pharmacodynamics, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor, following Multiple Ascending Doses in Patients with Chronic Hepatitis C Infection , 2012, Antimicrobial Agents and Chemotherapy.
[7] T. Hassanein,et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial , 2013, The Lancet.
[8] J. Emparanza,et al. [The prevalence of hepatitis C virus infection]. , 1998, Gastroenterologia y hepatologia.
[9] Brian L. Pearlman,et al. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] Feng Liu,et al. Long noncoding RNAs associated with liver regeneration 1 accelerates hepatocyte proliferation during liver regeneration by activating Wnt/β‐Catenin signaling , 2013, Hepatology.
[11] E. Ridruejo. Predictors of response to chronic hepatitis C treatment , 2012 .
[12] E. Schiff,et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. , 2013, The New England journal of medicine.
[13] M. Otto,et al. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. , 2010, Journal of medicinal chemistry.
[14] K. Reddy,et al. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection , 2013, Expert opinion on investigational drugs.
[15] O. Weiland,et al. Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.
[16] M. Gale,et al. Evasion of intracellular host defence by hepatitis C virus , 2005, Nature.
[17] B. Bell,et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.
[18] R. Schinazi,et al. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon‐ineligible/intolerant individuals , 2014, Hepatology.
[19] W. Symonds,et al. Pharmacokinetics, Safety, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor for Hepatitis C Virus, following Single Ascending Doses in Healthy Subjects , 2012, Antimicrobial Agents and Chemotherapy.
[20] M. Otto,et al. Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus , 2012, Antimicrobial Agents and Chemotherapy.
[21] R. Groszmann,et al. American association for the study of liver diseases , 1992 .
[22] M. Gale,et al. Regulation of hepatic innate immunity by hepatitis C virus , 2013, Nature Medicine.
[23] M. Manns,et al. Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.
[24] E. Lawitz,et al. 1130 THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF PSI-7977 IN HEPATITIS C INFECTED SUBJECTS TREATED FOR SEVEN DAYS , 2012 .
[25] K. Reddy,et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. , 2013, The Lancet. Infectious diseases.
[26] A. Lok,et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.
[27] C. Stedman,et al. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential , 2014, Therapeutic advances in gastroenterology.
[28] J. Murray,et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. , 2013, Gastroenterology.
[29] E. Lawitz,et al. The HCV NS5B nucleoside and non-nucleoside inhibitors. , 2011, Clinics in liver disease.
[30] F. Negro,et al. The global health burden of hepatitis C virus infection , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[31] S. Zeuzem,et al. Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon‐free treatment in the SOUND‐C2 study , 2013, Hepatology.
[32] C. Stedman,et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. , 2013, The New England journal of medicine.
[33] C. Stedman,et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. , 2014, Gastroenterology.
[34] Sprint Investigators,et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .
[35] M. Ghany,et al. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases , 2011, Hepatology.
[36] A. Gasbarrini,et al. Cost‐effectiveness of sofosbuvir‐based triple therapy for untreated patients with genotype 1 chronic hepatitis C , 2014, Hepatology.
[37] H. Mo,et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial , 2014, The Lancet.
[38] William M. Lee,et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. , 2009, The New England journal of medicine.
[39] D. Owens,et al. New Protease Inhibitors for the Treatment of Chronic Hepatitis C , 2012, Annals of Internal Medicine.
[40] H. Wedemeyer,et al. The clinical significance of drug–drug interactions in the era of direct‐acting anti‐viral agents against chronic hepatitis C , 2013, Alimentary pharmacology & therapeutics.
[41] K. Kowdley,et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. , 2013, Journal of hepatology.
[42] L. Prokunina-Olsson,et al. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. , 2014, The Journal of infectious diseases.
[43] M. Otto,et al. PSI-7851, a Pronucleotide of β-d-2′-Deoxy-2′-Fluoro-2′-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication , 2010, Antimicrobial Agents and Chemotherapy.
[44] M. Otto,et al. Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977 , 2010, The Journal of Biological Chemistry.
[45] J. Morales,et al. Transplantation in the patient with hepatitis C , 2009, Transplant international : official journal of the European Society for Organ Transplantation.
[46] N. Cammack,et al. GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796 , 2009, Antimicrobial Agents and Chemotherapy.
[47] E. Gane. The natural history of recurrent hepatitis C and what influences this , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[48] B. Bacon,et al. Chronic hepatitis C: an age wave of disease burden. , 2005, The American journal of managed care.
[49] R. Monina Klevens,et al. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007 , 2012, Annals of Internal Medicine.
[50] Brian L. Pearlman,et al. svr results of a once-daily regimen of simeprevir (tmc435) plus sofosbuvir (gs-7977) with or without ribavirin in cirrhotic and non-cirrhotic Hcv genotype 1 treatment-naïve and prior null responder patients: The Cosmos study : lb-3 , 2013 .
[51] P. Marcellin,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.
[52] Lisa S. Smith,et al. Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis C , 2011, The Annals of pharmacotherapy.
[53] E. Schiff,et al. Hepatitis C virus infection in USA: an estimate of true prevalence , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[54] Geoffrey Dusheiko,et al. Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.